NEWS RELEASE |
4Q17 3 months ended 03/31/17 | 3Q17 3 months ended 12/31/16 | + favorable / - unfavorable | |
Consolidated Revenue | $15.4M | $15.0M | +3% |
Net Income (Loss) | ($0.6M) | ($1.8M) | +69% |
Gross Margin | 44.0% | 40.4% | +3.6% |
Earnings (Loss) Per Share | ($0.01) | ($0.03) | +69% |
Non-GAAP Net Income (1) | $1.0M | $0.2M | +375% |
Non-GAAP Earnings Per Share (1) | $0.02 | $— | +375% |
Non-GAAP Adjusted EBITDA (1) | $1.2M | $0.5M | +142% |
(1) Please refer to the schedule at the end of this press release for a complete GAAP to non-GAAP reconciliation and other information related to non-GAAP financial measures. |
4Q17 3 months ended 03/31/17 | 3Q17 3 months ended 12/31/16 | + favorable / - unfavorable | |
IBW Segment Revenue | $6.9M | $6.2M | +12% |
IBW Segment Gross Margin | 42.2% | 40.3% | +1.9% |
IBW Segment R&D Expense | $1.5M | $1.3M | -13% |
IBW Segment Profit | $1.5M | $1.2M | +21% |
4Q17 3 months ended 03/31/17 | 3Q17 3 months ended 12/31/16 | + favorable / - unfavorable | |
ISMS Segment Revenue | $4.5M | $5.5M | -18% |
ISMS Segment Gross Margin | 56.2% | 50.6% | +5.6% |
ISMS Segment R&D Expense | $0.6M | $0.8M | +23% |
ISMS Segment Profit | $1.9M | $2.0M | -3% |
4Q17 3 months ended 03/31/17 | 3Q17 3 months ended 12/31/16 | + favorable / - unfavorable | |
CNS Segment Revenue | $3.9M | $3.2M | +20% |
CNS Segment Gross Margin | 32.7% | 23.1% | +9.6% |
CNS Segment R&D Expense | $0.3M | $0.3M | +15% |
CNS Segment Profit | $1.0M | $0.4M | +128% |
Three months ended | Twelve months ended | ||||||||||||||||||||
March 31, 2017 | December 31, 2016 | March 31, 2016 | March 31, 2017 | March 31, 2016 | |||||||||||||||||
Revenue: | |||||||||||||||||||||
Products | $ | 14,290 | $ | 12,746 | $ | 19,748 | $ | 56,530 | $ | 81,238 | |||||||||||
Services | 1,096 | 2,237 | 1,156 | 6,435 | 6,965 | ||||||||||||||||
Total revenue | $ | 15,386 | $ | 14,983 | $ | 20,904 | $ | 62,965 | $ | 88,203 | |||||||||||
Cost of revenue: | |||||||||||||||||||||
Products | 8,331 | 7,807 | 12,566 | 36,119 | 50,332 | ||||||||||||||||
Services | 292 | 1,122 | 445 | 3,097 | 3,355 | ||||||||||||||||
Total cost of revenue | 8,623 | 8,929 | 13,011 | 39,216 | 53,687 | ||||||||||||||||
Gross profit | 6,763 | 6,054 | 7,893 | 23,749 | 34,516 | ||||||||||||||||
Gross margin | 44.0 | % | 40.4 | % | 37.8 | % | 37.7 | % | 39.1 | % | |||||||||||
Operating expenses: | |||||||||||||||||||||
Research & development | 2,349 | 2,414 | 4,713 | 12,367 | 19,317 | ||||||||||||||||
Sales & marketing | 2,124 | 1,943 | 4,608 | 10,344 | 15,817 | ||||||||||||||||
General & administrative | 1,651 | 1,777 | 1,747 | 7,991 | 9,836 | ||||||||||||||||
Intangibles amortization | 1,151 | 1,212 | 1,305 | 4,764 | 5,554 | ||||||||||||||||
Restructuring | 100 | (1) | 490 | (1) | 731 | (2) | 3,155 | (1) | 748 | (2) | |||||||||||
Long-lived assets impairment | — | — | — | 1,181 | (3) | — | |||||||||||||||
Total operating expenses | 7,375 | 7,836 | 13,104 | 39,802 | 51,272 | ||||||||||||||||
Operating income (loss) from continuing operations | (612 | ) | (1,782 | ) | (5,211 | ) | (16,053 | ) | (16,756 | ) | |||||||||||
Other income (expense), net | 94 | (15 | ) | 107 | 170 | 169 | |||||||||||||||
Income (loss) before income taxes and discontinued operations | (518 | ) | (1,797 | ) | (5,104 | ) | (15,883 | ) | (16,587 | ) | |||||||||||
Income tax benefit (expense) | (38 | ) | (10 | ) | 27 | (58 | ) | 102 | |||||||||||||
Net income (loss) from continuing operations | (556 | ) | (1,807 | ) | (5,077 | ) | (15,941 | ) | (16,485 | ) | |||||||||||
Income (loss) from discontinued operations, net of income tax (4) | — | — | 1 | — | 273 | ||||||||||||||||
Net income (loss) | $ | (556 | ) | $ | (1,807 | ) | $ | (5,076 | ) | $ | (15,941 | ) | $ | (16,212 | ) | ||||||
Basic and diluted net income (loss) per share: | |||||||||||||||||||||
Basic and diluted net income (loss) from continuing operations | $ | (0.01 | ) | $ | (0.03 | ) | $ | (0.08 | ) | $ | (0.26 | ) | $ | (0.27 | ) | ||||||
Basic and diluted net income (loss) from discontinued operations | — | — | — | — | — | ||||||||||||||||
Basic and diluted net income (loss) | $ | (0.01 | ) | $ | (0.03 | ) | $ | (0.08 | ) | $ | (0.26 | ) | $ | (0.27 | ) | ||||||
Weighted-average number of shares outstanding: | |||||||||||||||||||||
Basic and diluted | 61,725 | 61,564 | 60,847 | 61,376 | 60,786 |
Assets: | March 31, 2017 (Unaudited) | March 31, 2016 | ||||||||
Cash and cash equivalents | $ | 21,778 | $ | 19,169 | ||||||
Short-term investments | — | 10,555 | ||||||||
Accounts receivable, net | 12,075 | 16,361 | ||||||||
Inventories | 12,511 | 13,498 | ||||||||
Prepaid expenses and other current assets | 1,409 | 1,900 | ||||||||
Total current assets | 47,773 | 61,483 | ||||||||
Property and equipment, net | 1,984 | 3,977 | ||||||||
Intangible assets, net | 15,624 | 20,388 | ||||||||
Other non-current assets | 160 | 183 | ||||||||
Total assets | $ | 65,541 | $ | 86,031 | ||||||
Liabilities and Stockholders’ Equity: | ||||||||||
Accounts payable | $ | 4,163 | $ | 7,856 | ||||||
Accrued expenses | 4,273 | 5,932 | ||||||||
Accrued restructuring | 1,171 | 1,537 | ||||||||
Contingent consideration | — | 311 | ||||||||
Deferred revenue | 2,359 | 1,601 | ||||||||
Total current liabilities | 11,966 | 17,237 | ||||||||
Deferred revenue non-current | 1,102 | 1,236 | ||||||||
Net deferred income tax liability | — | 10 | ||||||||
Accrued restructuring non-current | 63 | 550 | ||||||||
Other non-current liabilities | 236 | 314 | ||||||||
Total liabilities | 13,367 | 19,347 | ||||||||
Total stockholders’ equity | 52,174 | 66,684 | ||||||||
Total liabilities and stockholders’ equity | $ | 65,541 | $ | 86,031 |
Three months ended March 31, | Six months ended March 31, | Twelve months ended March 31, | ||||||||||||||
Cash flows from operating activities: | 2017 (Unaudited) | 2017 (Unaudited) | 2017 (Unaudited) | 2016 | ||||||||||||
Net income (loss) | $ | (556 | ) | $ | (2,363 | ) | $ | (15,941 | ) | $ | (16,212 | ) | ||||
Reconciliation of net income to net cash provided by (used in) operating activities: | ||||||||||||||||
Depreciation and amortization | 1,430 | 2,914 | 6,144 | 7,098 | ||||||||||||
Long-lived assets impairment | — | — | 1,181 | — | ||||||||||||
Stock-based compensation | 248 | 501 | 1,594 | 1,265 | ||||||||||||
Restructuring | 100 | 590 | 3,155 | 748 | ||||||||||||
Deferred taxes | (30 | ) | (24 | ) | (10 | ) | (36 | ) | ||||||||
Loss (gain) on sale of fixed assets | (28 | ) | 16 | 27 | 14 | |||||||||||
Exchange rate loss (gain) | 2 | 2 | 2 | (38 | ) | |||||||||||
Changes in assets and liabilities: | ||||||||||||||||
Accounts receivable | (817 | ) | 1,559 | 4,281 | (4,476 | ) | ||||||||||
Inventories | 478 | 167 | 987 | 2,707 | ||||||||||||
Accounts payable and accrued expenses | (2,768 | ) | (3,661 | ) | (9,570 | ) | 2,192 | |||||||||
Other | (34 | ) | 1,278 | 1,139 | 1,131 | |||||||||||
Net cash provided by (used in) operating activities | (1,975 | ) | 979 | (7,011 | ) | (5,607 | ) | |||||||||
Cash flows from investing activities: | ||||||||||||||||
Net purchases of short-term investments and debt securities | — | — | 10,555 | 13,351 | ||||||||||||
Proceeds from sale of assets | — | — | — | 264 | ||||||||||||
Purchases of property and equipment | (69 | ) | (98 | ) | (596 | ) | (1,932 | ) | ||||||||
Net cash provided by (used in) investing activities | (69 | ) | (98 | ) | 9,959 | 11,683 | ||||||||||
Cash flows from financing activities: | ||||||||||||||||
Payment of contingent consideration | — | — | (175 | ) | (808 | ) | ||||||||||
Purchases of treasury stock | (17 | ) | (22 | ) | (163 | ) | (108 | ) | ||||||||
Net cash provided by (used in) financing activities | (17 | ) | (22 | ) | (338 | ) | (916 | ) | ||||||||
Gain (loss) of exchange rate changes on cash | (3 | ) | 2 | (1 | ) | (17 | ) | |||||||||
Net increase (decrease) in cash and cash equivalents | (2,064 | ) | 861 | 2,609 | 5,143 | |||||||||||
Cash and cash equivalents, beginning of period | 23,842 | 20,917 | 19,169 | 14,026 | ||||||||||||
Cash and cash equivalents, end of period | $ | 21,778 | $ | 21,778 | $ | 21,778 | $ | 19,169 |
Three months ended March 31, 2017 | Three months Ended December 31, 2016 | |||||||||||||||||||||||||||||||
IBW | ISMS | CNS | Total | IBW | ISMS | CNS | Total | |||||||||||||||||||||||||
Revenue | $ | 6,944 | $ | 4,548 | $ | 3,894 | $ | 15,386 | $ | 6,224 | $ | 5,525 | $ | 3,234 | $ | 14,983 | ||||||||||||||||
Cost of revenue | 4,011 | 1,991 | 2,621 | 8,623 | 3,713 | 2,730 | 2,486 | 8,929 | ||||||||||||||||||||||||
Gross profit | 2,933 | 2,557 | 1,273 | 6,763 | 2,511 | 2,795 | 748 | 6,054 | ||||||||||||||||||||||||
Gross margin | 42.2 | % | 56.2 | % | 32.7 | % | 44.0 | % | 40.3 | % | 50.6 | % | 23.1 | % | 40.4 | % | ||||||||||||||||
Research & development | 1,473 | 619 | 257 | 2,349 | 1,307 | 805 | 302 | 2,414 | ||||||||||||||||||||||||
Segment profit | $ | 1,460 | $ | 1,938 | $ | 1,016 | $ | 4,414 | $ | 1,204 | $ | 1,990 | $ | 446 | $ | 3,640 |
Three months ended March 31, 2017 | Three months ended March 31, 2016 | |||||||||||||||||||||||||||||||
IBW | ISMS | CNS | Total | IBW | ISMS | CNS | Total | |||||||||||||||||||||||||
Revenue | $ | 6,944 | $ | 4,548 | $ | 3,894 | $ | 15,386 | $ | 5,838 | $ | 5,245 | $ | 9,821 | $ | 20,904 | ||||||||||||||||
Cost of revenue | 4,011 | 1,991 | 2,621 | 8,623 | 3,761 | 2,436 | 6,814 | 13,011 | ||||||||||||||||||||||||
Gross profit | 2,933 | 2,557 | 1,273 | 6,763 | 2,077 | 2,809 | 3,007 | 7,893 | ||||||||||||||||||||||||
Gross margin | 42.2 | % | 56.2 | % | 32.7 | % | 44.0 | % | 35.6 | % | 53.6 | % | 30.6 | % | 37.8 | % | ||||||||||||||||
Research & development | 1,473 | 619 | 257 | 2,349 | 2,421 | 1,471 | 821 | 4,713 | ||||||||||||||||||||||||
Segment profit (loss) | $ | 1,460 | $ | 1,938 | $ | 1,016 | $ | 4,414 | $ | (344 | ) | $ | 1,338 | $ | 2,186 | $ | 3,180 |
Twelve months ended March 31, 2017 | Twelve months ended March 31, 2016 | |||||||||||||||||||||||||||||||
IBW | ISMS | CNS | Total | IBW | ISMS | CNS | Total | |||||||||||||||||||||||||
Revenue | $ | 25,933 | $ | 19,321 | $ | 17,711 | $ | 62,965 | $ | 34,407 | $ | 21,783 | $ | 32,013 | $ | 88,203 | ||||||||||||||||
Cost of revenue | 17,262 | 9,543 | 12,411 | 39,216 | 20,463 | 10,661 | 22,563 | 53,687 | ||||||||||||||||||||||||
Gross profit | 8,671 | 9,778 | 5,300 | 23,749 | 13,944 | 11,122 | 9,450 | 34,516 | ||||||||||||||||||||||||
Gross margin | 33.4 | % | 50.6 | % | 29.9 | % | 37.7 | % | 40.5 | % | 51.1 | % | 29.5 | % | 39.1 | % | ||||||||||||||||
Research & development | 6,738 | 3,955 | 1,674 | 12,367 | 11,059 | 5,417 | 2,841 | 19,317 | ||||||||||||||||||||||||
Segment profit | $ | 1,933 | $ | 5,823 | $ | 3,626 | $ | 11,382 | $ | 2,885 | $ | 5,705 | $ | 6,609 | $ | 15,199 |
Twelve months ended March 31, 2017 | Twelve months ended March 31, 2016 | |||||||||||||||||||||
Revenue | Gross Profit | Gross Margin | Revenue | Gross Profit | Gross Margin | |||||||||||||||||
GAAP - IBW segment | $ | 25,933 | $ | 8,671 | 33.4 | % | $ | 34,407 | $ | 13,944 | 40.5 | % | ||||||||||
ClearLink DAS E&O (1) | — | 1,581 | — | — | ||||||||||||||||||
Stock-based compensation (2) | — | 9 | — | (3 | ) | |||||||||||||||||
Non-GAAP - IBW segment | $ | 25,933 | $ | 10,261 | 39.6 | % | $ | 34,407 | $ | 13,941 | 40.5 | % | ||||||||||
(1) Excess and Obsolete inventory charges on ClearLink DAS inventory and firm purchase commitments. | ||||||||||||||||||||||
(2) Stock-based compensation is a non-cash expense incurred in accordance with share-based compensation accounting standards. |
Three months ended March 31, 2017 | Three months ended December 31, 2016 | Three months ended March 31, 2016 | |||||||||||||||||||||||||||||||
Revenue | Gross Profit | Gross Margin | Revenue | Gross Profit | Gross Margin | Revenue | Gross Profit | Gross Margin | |||||||||||||||||||||||||
GAAP - Consolidated | $ | 15,386 | $ | 6,763 | 44.0 | % | $ | 14,983 | $ | 6,054 | 40.4 | % | $ | 20,904 | $ | 7,893 | 37.8 | % | |||||||||||||||
Deferred revenue adjustment (1) | 64 | 64 | 64 | 64 | 63 | 63 | |||||||||||||||||||||||||||
Stock-based compensation (3) | — | 10 | — | 10 | — | (29 | ) | ||||||||||||||||||||||||||
Non-GAAP - Consolidated | $ | 15,450 | $ | 6,837 | 44.3 | % | $ | 15,047 | $ | 6,128 | 40.7 | % | $ | 20,967 | $ | 7,927 | 37.8 | % |
Twelve months ended March 31, 2017 | Twelve months ended March 31, 2016 | |||||||||||||||||||||
Revenue | Gross Profit | Gross Margin | Revenue | Gross Profit | Gross Margin | |||||||||||||||||
GAAP - Consolidated | $ | 62,965 | $ | 23,749 | 37.7 | % | $ | 88,203 | $ | 34,516 | 39.1 | % | ||||||||||
Deferred revenue adjustment (1) | 254 | 254 | 281 | 281 | ||||||||||||||||||
ClearLink DAS E&O (2) | — | 1,581 | — | — | ||||||||||||||||||
Stock-based compensation (3) | — | 34 | — | (5 | ) | |||||||||||||||||
Non-GAAP - Consolidated | $ | 63,219 | $ | 25,618 | 40.5 | % | $ | 88,484 | $ | 34,792 | 39.3 | % |
Three months ended | Twelve months ended | |||||||||||||||||||
March 31, | December 31, | March 31, | March 31, | March 31, | ||||||||||||||||
2017 | 2016 | 2016 | 2017 | 2016 | ||||||||||||||||
GAAP consolidated operating expenses | $ | 7,375 | $ | 7,836 | $ | 13,104 | $ | 39,802 | $ | 51,272 | ||||||||||
Adjustments: | ||||||||||||||||||||
Stock-based compensation (3) | (238 | ) | (243 | ) | (320 | ) | (1,560 | ) | (1,270 | ) | ||||||||||
Long-lived asset impairment (4) | — | — | — | (1,181 | ) | — | ||||||||||||||
Amortization of intangibles (5) | (1,151 | ) | (1,212 | ) | (1,305 | ) | (4,764 | ) | (5,554 | ) | ||||||||||
Restructuring, separation, and transition (6) | (100 | ) | (490 | ) | (799 | ) | (3,155 | ) | (1,022 | ) | ||||||||||
Total adjustments | (1,489 | ) | (1,945 | ) | (2,424 | ) | (10,660 | ) | (7,846 | ) | ||||||||||
Non-GAAP consolidated operating expenses | $ | 5,886 | $ | 5,891 | $ | 10,680 | $ | 29,142 | $ | 43,426 |
Three months ended | Twelve months ended | |||||||||||||||||||
March 31, | December 31, | March 31, | March 31, | March 31, | ||||||||||||||||
2017 | 2016 | 2016 | 2017 | 2016 | ||||||||||||||||
GAAP consolidated net income (loss) | $ | (556 | ) | $ | (1,807 | ) | $ | (5,076 | ) | $ | (15,941 | ) | $ | (16,212 | ) | |||||
Income tax benefit (expense) | (38 | ) | (10 | ) | 27 | (58 | ) | 102 | ||||||||||||
Other income (expense), net | 94 | (15 | ) | 107 | 170 | 169 | ||||||||||||||
GAAP consolidated operating profit (loss) | $ | (612 | ) | $ | (1,782 | ) | $ | (5,210 | ) | $ | (16,053 | ) | $ | (16,483 | ) | |||||
Adjustments: | ||||||||||||||||||||
Deferred revenue adjustment (1) | 64 | 64 | 63 | 254 | 281 | |||||||||||||||
ClearLink DAS E&O (2) | — | — | — | 1,581 | — | |||||||||||||||
Stock-based compensation (3) | 248 | 253 | 291 | 1,594 | 1,265 | |||||||||||||||
Long-lived asset impairment (4) | — | — | — | 1,181 | — | |||||||||||||||
Amortization of intangibles (5) | 1,151 | 1,212 | 1,305 | 4,764 | 5,554 | |||||||||||||||
Restructuring, separation, and transition (6) | 100 | 490 | 799 | 3,155 | 1,022 | |||||||||||||||
Total adjustments | 1,563 | 2,019 | 2,458 | 12,529 | 8,122 | |||||||||||||||
Non-GAAP consolidated operating profit (loss) from continuing operations | $ | 951 | $ | 237 | $ | (2,752 | ) | $ | (3,524 | ) | $ | (8,361 | ) | |||||||
Depreciation | 279 | 272 | 458 | 1,380 | 1,544 | |||||||||||||||
Non-GAAP consolidated Adjusted EBITDA (7) from continuing operations | $ | 1,230 | $ | 509 | $ | (2,294 | ) | $ | (2,144 | ) | $ | (6,817 | ) |
Three months ended | Twelve months ended | |||||||||||||||||||
March 31, | December 31, | March 31, | March 31, | March 31, | ||||||||||||||||
2017 | 2016 | 2016 | 2017 | 2016 | ||||||||||||||||
GAAP consolidated net income (loss) | $ | (556 | ) | $ | (1,807 | ) | $ | (5,076 | ) | $ | (15,941 | ) | $ | (16,212 | ) | |||||
Adjustments: | ||||||||||||||||||||
Deferred revenue adjustment (1) | 64 | 64 | 63 | 254 | 281 | |||||||||||||||
ClearLink DAS E&O (2) | — | — | — | 1,581 | — | |||||||||||||||
Stock-based compensation (3) | 248 | 253 | 291 | 1,594 | 1,265 | |||||||||||||||
Long-lived asset impairment (4) | — | — | — | 1,181 | — | |||||||||||||||
Amortization of intangibles (5) | 1,151 | 1,212 | 1,305 | 4,764 | 5,554 | |||||||||||||||
Restructuring, separation, and transition (6) | 100 | 490 | 799 | 3,155 | 1,022 | |||||||||||||||
(Income) loss from discontinued operations (8) | — | — | (1 | ) | — | (273 | ) | |||||||||||||
Total adjustments | 1,563 | 2,019 | 2,457 | 12,529 | 7,849 | |||||||||||||||
Non-GAAP consolidated net income (loss) | $ | 1,007 | $ | 212 | $ | (2,619 | ) | $ | (3,412 | ) | $ | (8,363 | ) | |||||||
GAAP consolidated net income (loss) per common share: | ||||||||||||||||||||
Diluted | $ | (0.01 | ) | $ | (0.03 | ) | $ | (0.08 | ) | $ | (0.26 | ) | $ | (0.27 | ) | |||||
Non-GAAP consolidated net income (loss) per common share: | ||||||||||||||||||||
Diluted | $ | 0.02 | $ | — | $ | (0.04 | ) | $ | (0.06 | ) | $ | (0.14 | ) | |||||||
Average number of common shares outstanding: | ||||||||||||||||||||
Diluted | 62,115 | 61,700 | 60,847 | 61,376 | 60,786 |
(1) | On April 1, 2013, the Company purchased Kentrox. The acquisition required the step-down on acquired deferred revenue, which resulted in lower revenue that will not recur once those liabilities have fully settled. The adjustment removes the step-down on acquired deferred revenue that was recognized. |
(2) | Non-recurring excess and obsolete inventory charges on inventory and firm purchase commitments associated with the previously announced strategic decision related to the discontinuation of ClearLink DAS. |
(3) | Stock-based compensation is a non-cash expense incurred in accordance with share-based compensation accounting standards. |
(4) | Non-cash impairment related to tangible long-lived assets associated with the previously announced strategic decision related to the discontinuation of ClearLink DAS. |
(5) | Amortization of intangibles is a non-cash expense arising from previously acquired intangible assets. |
(6) | Restructuring expenses are not directly related to the ongoing performance of our fundamental business operations, including costs relating to abandonment of excess office space at our headquarters and in New Hampshire, and severance costs for terminated employees. This adjustment also includes severance benefits related to the departure of certain former executives. |
(7) | EBITDA is a non-GAAP measure that represents Earnings Before Interest, Taxes, Depreciation, and Amortization. The Company presents Adjusted EBITDA. |
(8) | This adjustment is a non-recurring charge related to the release of contingent liabilities related to the sale of ConferencePlus, which is presented as discontinued operations. |
Tom Minichiello Chief Financial Officer Westell Technologies, Inc. +1 (630) 375-4740 tminichiello@westell.com |